Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 320

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 320
---
; •the additional expenses and obligations to which Profusa’s business will be subject following the merger that Profusa has not previously been subject to, and the operational changes to Profusa’s business, in each case that may result from being a public company; •the fact that the representations and warranties in the Merger Agreement do not survive the closing of the merger and the potential risk of liabilities that may arise post -closing; and •various other risks associated with the combined organization and the merger, including the risks described in the section entitled “ Risk Factors” in this proxy statement/prospectus. The foregoing information is not intended to be exhaustive, but summarizes the material factors considered by the Profusa board of directors in its consideration of the Merger Agreement and the transactions contemplated. The Profusa board of directors concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. After considering these and other factors, the Profusa board of directors unanimously approved the Merger Agreement, the merger and the other transactions contemplated by the Merger Agreement. 162 Certain Persons in the Business Combination and Conflicts of Interest When you consider the recommendation of NorthView’s Board in favor of approval of the Business Combination Proposal, you should keep in mind that the Sponsor and certain of NorthView’s directors, officers and initial stockholders have interests in the Business Combination that are different from, or in addition to, your interests as a stockholder. These interests include, among other things: •the beneficial ownership of the Sponsor and certain of NorthView’s directors of an aggregate of 88.7% of outstanding NorthView Common Stock, which shares would become worthless if NorthView does not complete a business combination within the applicable time period, as the Sponsor and NorthView’s officers directors have waived any right to redemption with respect to these shares. Such shares have an aggregate market value of approximately $[] based on the closing price of NorthView Common Stock of $[•] on [•], 2025 the Record Date for the special meeting of stockholders; •the beneficial ownership of the Sponsor of 5,162,500 Private Placement Warrants, for which it paid $5,162,500 and which will expire and be worthless if NorthView does not complete a business combination within the applicable time period; •NorthView’s officers and directors have an aggregate of $560,833 invested in the Sponsor, which will be lost in the event that the Business Combination is not approved and concluded; •Certain of NorthView’s officers and